Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Hematology | Family Medicine
Search Medical Condition
Anemia Clinical Trials
A listing of Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (975) clinical trials
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US
Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in severity from mild (asymptomatic) to severe, anemia can result in ...
A 2 Part, Open Label, Intravenous, Single Ascending Dose Administrations of IOP Injection in Patients with Iron Deficient Anemia
This study is looking for the highest dose of investigational product we can give without it having any effects on you. The second part of the study is trying 2 different dosing time for the IP. You will be expected to stay in our Infusion Center and have blood samples ...
Autoimmune Hemolytic Anemia and Immune Thrombocytopenia
People with autoimmune hemolytic anemia and immune thrombocytopenia are asked to participate in a research study being conducted by Montefiore Medical Center.
Warm autoimmune haemolytic anemia (wAIHA)
People with warm autoimmune hemolytic anemia are asked to participate in a research study being conducted by Montefiore Medical Center.
Iron Deficiency Anemia
Fever? Aches? Pains? Cough? Sore Throat? When you reach for the tissues this flu season, think Global Medical Research. Global Medical Research is enrolling in a study that will try to find out if an investigational flu drug can speed up the recovery of people with flu.
Warm Antibody Autoimmune Hemolytic Anemia
People with autoimmune hemolytic anemia are asked to participate in a research study being conducted by Montefiore Medical Center.
Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphamide for GVHD Prophylaxis
Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, of those patients treated with immunosuppressive therapy, one quarter to one third will not respond, and about 50% of responders will relapse. Although allogeneic ...
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic stem and progenitor cells Immunosuppression is the definitive treatment of patients with acquired aplastic anemia who are not candidates for immediate hematopoietic stem cell transplantation. Horse ATG combined with the calcineurin inhibitor, cyclosporine (CsA), remains standard as first-line immunosuppressive therapy ...
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, of those patients treated with immunosuppressive therapy, one quarter to one third will not respond, and about 50 percent of responders will relapse. Allogeneic ...
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, of those patients treated with immunosuppressive therapy, one quarter to one third will not respond, and about 50% of responders will relapse. Combined haplo-cord ...
